PD-1およびPD-L1阻害剤の世界市場

PD-1およびPD-L1阻害剤の世界市場は2030年までに1,428億米ドルに到達

2024年に509億米ドルと推定されたPD-1およびPD-L1阻害剤の世界市場は、2024～2030年の分析期間においてCAGR 18.7%で成長し、2030年には1,428億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるPD-1阻害剤は、CAGR20.4%を記録し、分析期間終了時には1,011億米ドルに達すると予測されます。PD-L1阻害剤セグメントの成長率は、分析期間中CAGR 15.3%と推定されます。

米国市場は139億米ドルと推定、中国はCAGR 24.9％で成長すると予測

米国のPD-1およびPD-L1阻害剤市場は、2024年に139億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに325億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは24.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、それぞれ分析期間中に13.8%と17.0%のCAGRで成長すると予測されています。欧州では、ドイツがCAGR約15.0%で成長すると予測されています。

世界のPD-1およびPD-L1阻害剤市場- 主要動向と促進要因のまとめ

なぜPD-1およびPD-L1阻害剤が複数のがん種にわたる免疫療法に革命を起こしているのか？

プログラム細胞死タンパク質-1（PD-1）とそのリガンドであるPD-L1阻害剤は、免疫系が腫瘍細胞を認識し攻撃できるようにすることで、腫瘍学を根本的に変革しました。これらのチェックポイント阻害剤はPD-1/PD-L1経路を破壊し、がん細胞が免疫による検出を回避するために使用することで、T細胞の活性を回復させ、持続的な抗腫瘍反応を促進します。当初は転移性黒色腫、非小細胞肺がん（NSCLC）、腎細胞がんで承認されたが、現在ではトリプルネガティブ乳がん、肝細胞がん、尿路上皮がん、頭頸部がんなど幅広いがんで研究され、承認されています。

このクラスの免疫療法は、進行がんや難治性がんであっても、長期にわたって効果が持続することから支持されています。ペムブロリズマブ（キイトルーダ）、ニボルマブ（オプジーボ）、アテゾリズマブ（テセントリク）、デュルバルマブ（イムフィンジ）などの薬剤は、しばしば初回治療や維持療法として、がん治療レジメンの重要な柱となっています。PD-1/PD-L1阻害剤は現在、化学療法、標的療法、放射線療法と並行して、ネオアジュバント、アジュバント、併用療法で試験されており、がんの病期や治療ラインを越えてその適用が拡大しています。

バイオマーカー主導のアプローチと併用療法は、PD-1/PD-L1阻害の将来をどのように形作るのか？

PD-1およびPD-L1治療の成功には、バイオマーカー主導の患者選択が中心となってきています。PD-L1の発現レベル、腫瘍変異負荷（TMB）、マイクロサテライト不安定性（MSI）、腫瘍浸潤リンパ球（TIL）の存在は、反応者を同定し、治療レジメンを個別化するために使用されています。IHCアッセイや次世代シークエンシング（NGS）を含むコンパニオン診断法は、現在、有効性を最適化し、免疫関連有害事象（irAE）を最小化するために、臨床的意思決定に組み込まれています。

併用戦略は、このクラスで最も有望なフロンティアです。PD-1/PD-L1阻害剤とCTLA-4阻害剤（イピリムマブなど）、VEGF阻害剤（ベバシズマブなど）、低分子TKIを併用する試験で相乗効果が示されています。がんワクチン、CAR-T療法、マイクロバイオーム調節、オンコリューシスウイルスを含む新しいアプローチは、耐性を克服し、有効性を拡大するために評価されています。これらのマルチモーダル・アプローチにより、固形がんと血液悪性腫瘍の両方において、PD-1/PD-L1阻害の患者数と治療効果が大幅に拡大することが期待されます。

PD-1/PD-L1阻害療法の需要を牽引している適応症と地域市場は？

非小細胞肺がんは依然として最大の適応症であり、その高い有病率と確立されたバイオマーカーの枠組みにより、免疫腫瘍学の売上高の大きなシェアを占めています。メラノーマ、腎細胞がん、頭頸部扁平上皮がんも主要な治療領域です。子宮内膜がん、胃がん、食道がん、膀胱がんで新たな承認が得られつつあり、膠芽腫、卵巣がん、大腸がんで進行中の臨床試験がさらなる承認をもたらすと期待されています。

北米は、早期承認、有利な償還政策、強力な臨床試験インフラに牽引され、市場収益を独占しています。欧州がこれに続き、EMAや各国保健当局による承認取得が進んでいます。アジア太平洋は急成長している地域であり、特に中国と日本では国内企業がバイオシミラーや新規チェックポイント阻害薬の開発を進めています。がん免疫療法に対する急速な規制当局の承認と政府の投資が、活気に満ちた競合情勢に寄与しています。中東やラテンアメリカでは、がん研究助成金プログラムや多国籍企業との提携を通じて、徐々にアクセスが拡大しています。

PD-1/PD-L1阻害剤市場の長期的成長と戦略的革新の原動力は？

PD-1/PD-L1阻害薬市場の成長の原動力は、がん罹患率の増加、適応拡大、併用療法および次世代免疫療法の強固な臨床パイプラインです。免疫腫瘍学ががん治療の中心的存在となるにつれ、大手製薬企業、バイオテクノロジー新興企業、学術機関からの投資が、新たな適応症、予測バイオマーカー、耐性メカニズムの調査に拍車をかけています。ゲノミクス、リアルワールドエビデンス、AIベースの試験デザインの融合は、イノベーションと市場参入戦略を加速させています。

戦略的には、企業は新たな剤形（皮下注射）、早期治療ラインへの拡大、バイオマーカーに連動した価格設定モデルによるライフサイクル管理に注力しています。戦略的提携、ライセンシング契約、世界な共同商業化契約は、市場のダイナミクスを再構築しています。PD-1/PD-L1バイオシミラーや費用対効果の高いチェックポイント治療薬の開発は、価格に敏感な市場でのアクセスを改善すると予想されます。免疫療法が固形がんや血液悪性腫瘍の主力治療薬となる中、PD-1/PD-L1阻害剤は、科学的ブレークスルー、臨床的有用性、世界の健康への影響の融合によって、今後も腫瘍学的イノベーションの最前線に位置し続けるでしょう。

セグメント

阻害剤の種類（PD-1阻害剤、PD-L1阻害剤）;がんの種類（腎臓がん、黒色腫、膀胱がん、非小細胞肺がん、肝臓がん、頭頸部がん、その他のがん）;販売チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の34社）

• AbbVie Inc.
• Akeso Inc.
• Amgen Inc.
• AstraZeneca plc
• BeiGene, Ltd.
• BioNTech SE
• Bristol-Myers Squibb Company
• CStone Pharmaceuticals
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc
• Innovent Biologics, Inc.
• Jiangsu Hengrui Medicine Co., Ltd.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi S.A.
• Shanghai Junshi Biosciences Co., Ltd.
• Takeda Pharmaceutical Company Limited

関税影響係数

Global Industry Analystsは、本社国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global PD-1 and PD-L1 Inhibitors Market to Reach US$142.8 Billion by 2030

The global market for PD-1 and PD-L1 Inhibitors estimated at US$50.9 Billion in the year 2024, is expected to reach US$142.8 Billion by 2030, growing at a CAGR of 18.7% over the analysis period 2024-2030. PD-1 Inhibitors, one of the segments analyzed in the report, is expected to record a 20.4% CAGR and reach US$101.1 Billion by the end of the analysis period. Growth in the PD-L1 Inhibitors segment is estimated at 15.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.9 Billion While China is Forecast to Grow at 24.9% CAGR

The PD-1 and PD-L1 Inhibitors market in the U.S. is estimated at US$13.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$32.5 Billion by the year 2030 trailing a CAGR of 24.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.8% and 17.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.0% CAGR.

Global PD-1 and PD-L1 Inhibitors Market - Key Trends & Drivers Summarized

Why Are PD-1 and PD-L1 Inhibitors Revolutionizing Immunotherapy Across Multiple Cancer Types?

Programmed cell death protein-1 (PD-1) and its ligand PD-L1 inhibitors have fundamentally transformed oncology by enabling the immune system to recognize and attack tumor cells. These checkpoint inhibitors disrupt the PD-1/PD-L1 pathway-used by cancer cells to evade immune detection-restoring T-cell activity and facilitating a durable anti-tumor response. Initially approved for metastatic melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma, PD-1 and PD-L1 inhibitors are now being investigated and approved for a wide array of cancers, including triple-negative breast cancer, hepatocellular carcinoma, urothelial carcinoma, and head and neck cancers.

This class of immunotherapy is favored for its ability to produce long-lasting responses, even in advanced or refractory cancers. Drugs such as pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab (Tecentriq), and durvalumab (Imfinzi) have become key pillars in oncology regimens, often as first-line or maintenance therapies. PD-1/PD-L1 inhibitors are now being trialed in neoadjuvant, adjuvant, and combination settings alongside chemotherapy, targeted therapy, and radiation, expanding their application across cancer stages and treatment lines.

How Are Biomarker-Driven Approaches and Combination Therapies Shaping the Future of PD-1/PD-L1 Inhibition?

Biomarker-driven patient selection is becoming central to the success of PD-1 and PD-L1 therapies. Expression levels of PD-L1, tumor mutation burden (TMB), microsatellite instability (MSI), and the presence of tumor-infiltrating lymphocytes (TILs) are being used to identify responders and personalize treatment regimens. Companion diagnostics, including IHC assays and next-generation sequencing (NGS), are now integrated into clinical decision-making to optimize efficacy and minimize immune-related adverse events (irAEs).

Combination strategies are the most promising frontier in this class. Trials combining PD-1/PD-L1 inhibitors with CTLA-4 blockers (e.g., ipilimumab), VEGF inhibitors (e.g., bevacizumab), and small molecule TKIs are showing synergistic effects. Novel approaches involving cancer vaccines, CAR-T therapy, microbiome modulation, and oncolytic viruses are being evaluated to overcome resistance and broaden efficacy. These multi-modal approaches are expected to significantly expand the patient pool and therapeutic benefit of PD-1/PD-L1 inhibition in both solid tumors and hematologic malignancies.

Which Indications and Regional Markets Are Driving Demand for PD-1 and PD-L1 Inhibitor Therapies?

Non-small cell lung cancer remains the largest indication for PD-1 and PD-L1 inhibitors, accounting for a significant share of immuno-oncology sales due to its high prevalence and well-established biomarker frameworks. Melanoma, renal cell carcinoma, and head and neck squamous cell carcinoma also constitute major treatment areas. Emerging approvals in endometrial, gastric, esophageal, and bladder cancers are expanding market scope, with ongoing trials in glioblastoma, ovarian, and colorectal cancers expected to yield additional approvals.

North America dominates market revenue, driven by early approvals, favorable reimbursement policies, and strong clinical trial infrastructure. Europe follows, with increasing uptake through the EMA and national health authorities. Asia-Pacific is the fastest-growing region, particularly in China and Japan, where domestic companies are developing biosimilars and novel checkpoint inhibitors. Rapid regulatory approvals and government investments in cancer immunotherapy are contributing to a vibrant, competitive landscape. The Middle East and Latin America are gradually expanding access via oncology funding programs and multinational partnerships.

What Is Driving Long-Term Growth and Strategic Innovation in the PD-1/PD-L1 Inhibitors Market?

The growth in the PD-1 and PD-L1 inhibitors market is driven by increasing cancer incidence, broader label expansions, and the robust clinical pipeline of combination and next-generation immunotherapies. As immuno-oncology becomes central to cancer care pathways, investment from Big Pharma, biotech startups, and academic institutions is fueling research into new indications, predictive biomarkers, and resistance mechanisms. The convergence of genomics, real-world evidence, and AI-based trial design is accelerating innovation and market access strategies.

Strategically, companies are focusing on lifecycle management through new dosage forms (subcutaneous injections), expansion into earlier treatment lines, and biomarker-linked pricing models. Strategic alliances, licensing deals, and global co-commercialization agreements are reshaping market dynamics. The development of PD-1/PD-L1 biosimilars and cost-effective checkpoint alternatives is expected to improve access in price-sensitive markets. As immunotherapy becomes a mainstay across solid tumors and hematologic malignancies, PD-1/PD-L1 inhibitors will remain at the forefront of oncologic innovation, driven by a blend of scientific breakthroughs, clinical utility, and global health impact.

SCOPE OF STUDY:

The report analyzes the PD-1 and PD-L1 Inhibitors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type of Inhibitor (PD-1 Inhibitors, PD-L1 Inhibitors); Cancer Type (Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck, Other Cancer Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• AbbVie Inc.
• Akeso Inc.
• Amgen Inc.
• AstraZeneca plc
• BeiGene, Ltd.
• BioNTech SE
• Bristol-Myers Squibb Company
• CStone Pharmaceuticals
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc
• Innovent Biologics, Inc.
• Jiangsu Hengrui Medicine Co., Ltd.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi S.A.
• Shanghai Junshi Biosciences Co., Ltd.
• Takeda Pharmaceutical Company Limited

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • PD-1 and PD-L1 Inhibitors - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Cancer Burden Propels Demand for Immuno-Oncology Agents Targeting PD-1 and PD-L1
  • Expansion of Indications Beyond Melanoma and NSCLC Drives Market Diversification for Checkpoint Inhibitors
  • Breakthrough Approvals and Accelerated Review Pathways Throw the Spotlight on PD-1/PD-L1 Drug Pipelines
  • Growing Investment in Combination Therapies Strengthens Business Case for Synergistic Cancer Treatment
  • Emergence of Biomarker-Driven Patient Selection Enhances Clinical Outcomes and Cost-Effectiveness
  • Rapid Expansion of Clinical Trials in Rare and Hard-to-Treat Cancers Supports Label Expansion
  • Adoption of Companion Diagnostics and Tumor Profiling Supports Personalized Immunotherapy Protocols
  • Rising Emphasis on Real-World Evidence Collection Enhances Market Access and Payer Negotiations
  • Availability of Subcutaneous and Long-Acting Formulations Drives Patient Convenience and Compliance
  • Integration of Artificial Intelligence in Trial Design Accelerates Immunotherapy Development Pipelines
  • Collaborations Between Pharma and Academic Institutions Fuel Discovery of Novel Checkpoint Targets
  • Price Competition From Biosimilars and Global Reference Products Spurs Cost Optimization Strategies
  • Growth in Neoantigen Vaccine Research Creates Synergies With PD-1/PD-L1 Blockade Therapies
  • Use of PD-1/PD-L1 Inhibitors in Neoadjuvant and Adjuvant Settings Expands Clinical Application Scope
  • Regulatory Support for Tumor-Agnostic Therapies Strengthens Positioning in Precision Oncology
  • Development of Next-Generation Checkpoint Modulators Enhances Efficacy in Resistant Patient Populations
  • Increased Reimbursement in Developed Markets Encourages Broader Adoption Across Oncology Centers
  • Challenges in Immune-Related Adverse Events Drive Development of Predictive Risk Models
  • Global Disparities in Access to Immunotherapy Highlight Opportunities for Tiered Pricing and Localization
  • Strategic Licensing and Co-Development Agreements Accelerate Commercial Footprint in Competitive Markets
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World PD-1 and PD-L1 Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for PD-1 and PD-L1 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for PD-1 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for PD-1 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for PD-1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for PD-L1 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for PD-L1 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for PD-L1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Kidney by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Kidney by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Kidney by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Bladder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Bladder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Bladder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Non-small Cell Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Non-small Cell Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Non-small Cell Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Liver by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Head & Neck by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Head & Neck by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Head & Neck by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• JAPAN
  • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• CHINA
  • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 68: China Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• EUROPE
  • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for PD-1 and PD-L1 Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• FRANCE
  • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 89: France Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• GERMANY
  • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 107: Italy Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 116: UK Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 125: Spain Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 134: Russia Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for PD-1 and PD-L1 Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• AUSTRALIA
  • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 164: Australia Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• INDIA
  • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 173: India Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for PD-1 and PD-L1 Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for PD-1 and PD-L1 Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 260: Iran Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 269: Israel Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 287: UAE Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
• AFRICA
  • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 305: Africa Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030

IV. COMPETITION